In a U.S. cohort of IBD patients, anti-TNF therapy was found to be a protective factor for the development of CRC in both CD and UC (OR = 0.69, 95% CI = 0.66–0.73, p < 0.0001; and OR = 0.78, 95% CI = 0.73–0.83, p < 0.0001) [89]. This evidence concerns the gene TNF and inflammatory bowel disease.